AMP Starts a Position in Redhill Biopharma


Today, AMP started an initial position totaling $12,495 in Redhill Biopharma (RDHL) by buying 1,279 shares at a price of $9.77. Redhill Biopharma is an Israeli based company developing orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

Redhill has two marketed products, Donnatal® (a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis) and EnteraGam® - a medical food intended for the dietary management of chronic diarrhea and loose stools. It's most advanced clinical assets are in migraines, h pylori infections, gastritis, and Crohn's disease.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon